138 related articles for article (PubMed ID: 9332769)
1. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.
Boiko IV; Mitchell MF; Pandey DK; White RA; Hu W; Malpica A; Nishioka K; Boone CW; Atkinson EN; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):849-55. PubMed ID: 9332769
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
Boiko IV; Mitchell MF; Hu W; Pandey DK; Mathevet P; Malpica A; Hittelman WN
Clin Cancer Res; 1998 Jun; 4(6):1383-91. PubMed ID: 9626454
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
4. Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.
Poulin N; Boiko I; MacAulay C; Boone C; Nishioka K; Hittelman W; Mitchell MF
Cytometry; 1999 Oct; 38(5):214-23. PubMed ID: 10516607
[TBL] [Abstract][Full Text] [Related]
5. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.
Bacus JW; Boone CW; Bacus JV; Follen M; Kelloff GJ; Kagan V; Lippman SM
Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1087-94. PubMed ID: 10613341
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3.
Vlastos AT; West LA; Atkinson EN; Boiko I; Malpica A; Hong WK; Follen M
Clin Cancer Res; 2005 Jan; 11(1):390-6. PubMed ID: 15671570
[TBL] [Abstract][Full Text] [Related]
7. [Study on nuclear DNA content and image cytometry in cervical cancer and precursor lesions].
Jiao Y; Zhou X; Ma S
Zhonghua Fu Chan Ke Za Zhi; 2001 May; 36(5):267-70. PubMed ID: 11783373
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic use of DNA image cytometry in cervical squamous intraepithelial lesions and invasive carcinoma.
Böcking A; Nguyen VQ
Cancer; 2004 Feb; 102(1):41-54. PubMed ID: 14968417
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of cervical intraepithelial neoplasia (CIN) lesions by DNA image cytometry].
Sun XR; Che DY; Tu HZ; Li D; Wang J
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):831-5. PubMed ID: 17416004
[TBL] [Abstract][Full Text] [Related]
11. Polyamines as biomarkers of cervical intraepithelial neoplasia.
Nishioka K; Melgarejo AB; Lyon RR; Mitchell MF
J Cell Biochem Suppl; 1995; 23():87-95. PubMed ID: 8747382
[TBL] [Abstract][Full Text] [Related]
12. Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.
Zou C; Vlastos AT; Yang L; Wang J; Nishioka K; Follen M
Gynecol Oncol; 2002 May; 85(2):266-73. PubMed ID: 11972386
[TBL] [Abstract][Full Text] [Related]
13. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
14. Applicability of liquid-based cytology to the assessment of DNA content in cervical lesions using static cytometry.
Shirata NK; Longatto Filho A; Roteli-Martins C; Espoladore LM; Pittoli JE; Syrjänen K
Anal Quant Cytol Histol; 2003 Aug; 25(4):210-4. PubMed ID: 12961827
[TBL] [Abstract][Full Text] [Related]
15. Nuclear DNA content analysis by static cytometry in cervical intraepithelial lesions using retrospective series of previously stained PAP smears.
Shirata NK; Gomes NS; Garcia EA; Longatto Filho A
Adv Clin Path; 2001 Jul; 5(3):87-91. PubMed ID: 11753880
[TBL] [Abstract][Full Text] [Related]
16. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
17. Cytometric evidence that cervical intraepithelial neoplasia I and II are dysplasias rather than true neoplasias. An image analysis study of factors involved in the progression of cervical lesions.
Mariuzzi G; Santinelli A; Valli M; Sisti S; Montironi R; Mariuzzi L; Alberti R; Pisani E
Anal Quant Cytol Histol; 1992 Apr; 14(2):137-47. PubMed ID: 1590897
[TBL] [Abstract][Full Text] [Related]
18. DNA quantification in cervical intraepithelial neoplasia thick tissue sections by confocal laser scanning microscopy.
Crist KA; Kim K; Goldblatt PJ; Boone CW; Kelloff GJ; You M
J Cell Biochem Suppl; 1996; 25():49-56. PubMed ID: 9027598
[TBL] [Abstract][Full Text] [Related]
19. Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR.
Yamal JM; Cox D; Hittelman WN; Boiko I; Malpica A; Guillaud M; MacAulay C; Follen M; Vlastos AT
Gynecol Oncol; 2004 Aug; 94(2):296-306. PubMed ID: 15297165
[TBL] [Abstract][Full Text] [Related]
20. DNA image cytometry parameters to identify high-grade cervical lesions.
Costa AF; Pogere A; Pasinato APBF; Onofre ASC; Onofre FBM
Cytopathology; 2022 Sep; 33(5):563-571. PubMed ID: 35340056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
